{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:54:30Z","timestamp":1787507670077,"version":"build-2736575974"},"reference-count":26,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:00:00Z","timestamp":1714003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2024,4,11]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperactivity of epithelial sodium channel (ENaC) with increased sodium absorption is a feature of cystic fibrosis (CF). ION-827359 is a 2.5-generation antisense oligonucleotide targeted to reduce ENaC protein. This study evaluated ION-827359 safety, pharmacokinetics and pharmacodynamics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this three-part phase 1\/2a, double-blind, randomised study, healthy volunteers received single doses of placebo or ION-827359 (3, 10, 37.5 or 100\u2005mg; Part 1) or multiple doses of placebo or ION-827359 (5\u00d710\u2005mg, 5\u00d737.5\u2005mg, 5\u00d775\u2005mg or 10\u00d737.5\u2005mg; Part 2). People with CF (pwCF) received multiple doses of placebo or ION-827359 (5\u00d710\u2005mg, 5\u00d737.5\u2005mg, 5\u00d775\u2005mg and 5\u00d7100\u2005mg; Part 3). Treatments were administered\n                      <jats:italic>via<\/jats:italic>\n                      Pari eFlow\n                      <jats:sup>\u00a9<\/jats:sup>\n                      mesh nebuliser. The primary outcome was safety; pharmacokinetic and pharmacodynamic parameters were also assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      64 healthy volunteers and 34 pwCF were enrolled. ION-827359 was well tolerated with an acceptable safety profile. There were no clinically relevant changes in laboratory values, ECG or vital signs. Systemic drug exposure was low (plasma half-life \u223c2\u2005weeks). Multiple doses of ION-827359 were associated with dose-dependent reductions in ENaC mRNA in bronchial epithelium. After multiple dosing, forced expiratory volume in 1\u2005s was slightly higher in pwCF receiving ION-827359 (+2.9% with ION-827359 100\u2005mg\n                      <jats:italic>versus<\/jats:italic>\n                      placebo; p=0.27).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The tolerability and safety of ION-827359 appear favourable at this stage of investigation. Reduction in ENaC mRNA supports mechanistic efficacy at the doses and regimens tested, and supports further investigation of ION-827359 in pwCF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.00986-2023","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T12:00:31Z","timestamp":1714046431000},"page":"00986-2023","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Randomised, phase 1\/2a trial of ION-827359, an antisense oligonucleotide inhibitor of ENaC"],"prefix":"10.1183","volume":"10","author":[{"given":"Sivagurunathan","family":"Sutharsan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainald","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Gleiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1828-0058","authenticated-orcid":false,"given":"Alex","family":"Horsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Crosby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Stuart","family":"Elborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,4,25]]},"reference":[{"key":"2024101712250000000_10.4.00986-2023.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201404-0670OC"},{"key":"2024101712250000000_10.4.00986-2023.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60327-5"},{"key":"2024101712250000000_10.4.00986-2023.3","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2024101712250000000_10.4.00986-2023.4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)00576-6"},{"key":"2024101712250000000_10.4.00986-2023.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201910-1943so"},{"key":"2024101712250000000_10.4.00986-2023.6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1513\/AnnalsATS.201907-493OC","article-title":"Changes in airway microbiome and inflammation with ivacaftor treatment in patients with cystic fibrosis and the G551D mutation","volume":"17","author":"Harris","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2024101712250000000_10.4.00986-2023.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201609-1954OC"},{"key":"2024101712250000000_10.4.00986-2023.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908639"},{"key":"2024101712250000000_10.4.00986-2023.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709847"},{"key":"2024101712250000000_10.4.00986-2023.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709846"},{"key":"2024101712250000000_10.4.00986-2023.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409547"},{"key":"2024101712250000000_10.4.00986-2023.12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"key":"2024101712250000000_10.4.00986-2023.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2018.09.007"},{"key":"2024101712250000000_10.4.00986-2023.14","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.369520"},{"key":"2024101712250000000_10.4.00986-2023.15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100313"},{"key":"2024101712250000000_10.4.00986-2023.16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00228013"},{"key":"2024101712250000000_10.4.00986-2023.17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.36.040196.000543"},{"key":"2024101712250000000_10.4.00986-2023.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-009-0733-4"},{"key":"2024101712250000000_10.4.00986-2023.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.05.003"},{"key":"2024101712250000000_10.4.00986-2023.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2018.07.006"},{"key":"2024101712250000000_10.4.00986-2023.21","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034805"},{"key":"2024101712250000000_10.4.00986-2023.22","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2013.1037"},{"key":"2024101712250000000_10.4.00986-2023.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00946-2020"},{"key":"2024101712250000000_10.4.00986-2023.24","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.11.1419"},{"key":"2024101712250000000_10.4.00986-2023.25","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.106.012401"},{"key":"2024101712250000000_10.4.00986-2023.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043891"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00986-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:37:00Z","timestamp":1740357420000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00986-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,9,16]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1183\/23120541.00986-2023"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00986-2023","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,25]]}}}